Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

DISEASE CHARACTERISTICS:

• Completely resected histologically confirmed adenocarcinoma of the colon

  • High-risk stage II disease, including one of the following:

    • T4 lesions
    • Less than 12 sampled lymph nodes
    • Poorly differentiated histology
  • Stage III disease, defined as having at least one pathologically confirmed positive lymph node or one pathologically confirmed positive tumour deposit.
  • Synchronous primary colon cancer allowed
• Adjuvant chemotherapy treatment for colon cancer with a 5-fluorouracil- based regimen received with an intent to provide a complete course of treatment. While one current standard is 24 weeks of treatment, patients who are pre-planned to receive a shorter duration of chemotherapy, including as part of a research study will also be permitted. The actual treatment received may be less than 24 weeks; participants must have received a minimum of one treatment cycle.
• Chemotherapy must have been completed (i.e. last dose received) a minimum of 60 days and a maximum of 180 days prior to registration.
• Carcinoembryonic antigen (CEA) ≤ 5 μg/L
• Current physical activity levels do not meet the recommended guidelines (≥ 150 minutes of moderate-to-vigorous or ≥ 75 minutes of vigorous physical activity/week) as calculated using the Leisure Time Exercise Questionnaire (LTEQ)
• No metastatic or locally recurrent disease as assessed by chest x-ray or CT scan and CT, MRI or Ultrasound of the abdomen/pelvis.
• No rectal cancer

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Absolute granulocyte count ≥ 1,000/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 100 g/L
• Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• Alkaline phosphatase < 2.5 times ULN
• AST or ALT < 2 times ULN
• Not pregnant or planning to become pregnant within the next 3 years
• Able (i.e., sufficiently fluent) and willing to effectively communicate with the physical activity consultant affiliated with the originating cancer center
• Able (i.e., sufficiently fluent in English or French) and willing to complete the patient-reported outcome questionnaires, social determinants of exercise measurement, health economics, and physical activity questionnaires and logs
• Able to complete the baseline exercise test
• No significant comorbid conditions precluding participation in a physical activity program as determined by the investigator
• Likely to participate in a physical activity program, as assessed by the investigator
• No history of other malignancies, except adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, other solid tumors, Hodgkin lymphoma, or non-Hodgkin lymphoma curatively treated with no evidence of disease for > 5 years

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior radiotherapy as a component of treatment for primary tumor
• No concurrent treatment with additional chemotherapy or radiation
• No concurrent treatment with any medications deemed by the investigator as likely to preclude participation in a physical activity program
• No concurrent anticancer treatment including chemotherapy, biological, or targeted agents